Reimagining drug development

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Jen Nwankwo, Founder and CEO at 1910 Genetics.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Jen, covering:

• Being the first PHD at Bain’s Global HQ, and what she learned from the experience
• How she stumbled across AI and open innovation as it applied to R&D productivity, and accelerating clinical trials
• The founding story of 1910, and fundraising as an African American female entrepreneur and going on to be backed by Sam Altman, CEO of OpenAI, Y Combinator and Microsoft…
• Signing a five-year agreement with Microsoft to create an AI-driven drug discovery and development platform that helps R&D teams generate drugs faster and cheaper
• Why artisanal and serendipitous drug development does not cut it. And the spectrum of AI experts Vs AI novices in pharma… and why a ‘FOMO attitude’ will lead to ‘pilot fatigue’, and slow adoption

Before founding 1910, Jen worked at the intersection of life science, technology, and business. Prior roles include Management Consultant at Bain & Company, Director of Business Development at a health-tech startup (pre-seed to Series A), and drug discovery stints at Novartis and Eli Lilly. During her Ph.D. research, Jen was an HHMI Predoctoral Fellow at the medical schools of Tufts University and Harvard University.

See you at TIDES Europe!

The Molecule to Market team, will be attending the event in Hamburg this November. As a special offer for our listeners, the TIDES team is providing a 10% discount on event passes. Use the code M2M15 or follow this link to claim your discount!

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

This episode of Molecule to Market is sponsored by Vetter, a global leader in aseptic filling solutions for injectable products in the pharmaceutical and biotech industries. Discover more about Vetter’s comprehensive services, from early-stage development to commercial production, and how they support clients in delivering high-quality therapies to the market.

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.